<DOC>
	<DOCNO>NCT00405392</DOCNO>
	<brief_summary>This randomize open label , multi-centre study Korean woman postmenopausal osteoporosis , evaluate preference either once-monthly dosing ibandronate once-weekly dosing risedronate . Eligible subject randomise either ibandronate monthly regimen risedronate weekly regimen . Treatment period consist 3 month ibandronate 150mg additional 12 week risedronate 35 mg vice versa . After take first interventional medicine 3 month 12 week completely , subject change treatment arm . There washout period .</brief_summary>
	<brief_title>Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<criteria>Women postmenopausal osteoporosis diagnose DXA scanning , define Tscore 2.5 SD spine femur . Patients never receive bisphosphonates therapy ( bisphosphonates naive ) Inability stand sit upright position least 60 minute ; Hypersensitivity component risedronate ibandronate ; Administration investigational drug within 30 day precede first dose study drug ; Patient hormone ( estrogen ) replacement therapy osteoporosis medication ( e.g . SERMS calcitonin ) within previous 3 month . Patient systemic corticosteroid therapy 1 month within past year . Other bone disease except osteoporosis Current medical history uncontrolled major upper GI disease</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Ibandronate</keyword>
	<keyword>risedronate</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>preference</keyword>
</DOC>